Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Analysis of the Microbiome in Rosacea
NCT04108897Phase 1Active, not recruiting
- Sponsor
- Johns Hopkins University
- Start
- Sep 2019
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of doxycycline and ivermectin in rosacea (6 arms), sponsored by Johns Hopkins University. Primary endpoint: Difference in skin and gut microbiome between rosacea and control at 2 months. Started Sep 2019; status: active, not recruiting.
02
Drugs
doxycyclineivermectin
03
Conditions
rosacea
Beyond the preview
Go deeper on NCT04108897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04108897.